Announcements Trials
Browse Landscape

Phase

Phase 1/2 5Phase 2 3Phase 1 3

Status

Completed 5

Sponsor Class

NIH 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Sarcoma 5CNS 5

Conditions

Multiple Myeloma 7Hematologic Neoplasms 7Graft vs Host Disease 5Gliosarcoma 5Glioblastoma 5Brain Neoplasms 5Prostatic Neoplasms 4Myelodysplastic Syndromes 4Lymphoma, Non-Hodgkin 4Waldenstrom Macroglobulinemia 3Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Hodgkin Disease 3Carcinoma, Non-Small-Cell Lung 3Tuberous Sclerosis 2Oligodendroglioma 2Neurofibrosarcoma 2Myeloproliferative Disorders 2Lymphoma, Mantle-Cell 2Lymphoma 2Lung Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Glioma 2Burkitt Lymphoma 2Bronchiolitis Obliterans Syndrome 2

Interventions

Temozolomide 26Bevacizumab 14Radiosurgery 12Radiotherapy 9pembrolizumab 8Carboplatin 8Trastuzumab 6temsirolimus 5Sirolimus 5Erlotinib Hydrochloride 5abemaciclib 4Paclitaxel 4Irinotecan 4Capecitabine 4tipifarnib 3Sorafenib 3Radiation 3Mental Status and Dementia Tests 3Ipilimumab 3Everolimus 3Aminolevulinic Acid 3130-nm albumin-bound paclitaxel 3tucatinib 2pertuzumab 2fludarabine 2durvalumab 2alovudine 2alectinib 2Vorinostat 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Brain Neoplasms × Sirolimus × Clear all
NCT01051557 2021-07-19

Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
36 enrolled 15 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00047073 2020-08-03

Sirolimus in Treating Patients With Glioblastoma Multiforme

Jonsson Comprehensive Cancer Center

Phase 1/2 Completed
13 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00329719 2018-10-16

Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1/2 Completed
115 enrolled 13 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00335764 2018-07-02

Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

National Cancer Institute (NCI)

Phase 1/2 Completed
92 enrolled 24 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00112736 2015-06-15

Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
69 enrolled 12 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡